-

04:11:01 PM

PLRX Stock News

PLRX - Pliant Therapeutics Inc

06/24/22 8:00 AM

Nasdaq : PLRX

clinical trial

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientific posters at the

RHEA-AI

neutral

06/22/22 8:00 AM

Nasdaq : PLRX

clinical trial

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α 7 β 1

RHEA-AI

neutral

06/16/22 8:00 AM

Nasdaq : PLRX

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Integrin target selected for development under 2019 collaboration following successful validation by Pliant Pliant to receive $4 million milestone payment and reimbursement in support of initiation of research and development activities SOUTH SAN FRANCISCO, Calif., June 16, 2022

RHEA-AI

very positive

06/15/22 4:01 PM

Nasdaq : PLRX

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present two scientific

RHEA-AI

neutral

05/18/22 11:15 AM

Nasdaq : PLRX

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company presented five scientific posters

RHEA-AI

neutral

05/11/22 8:00 AM

Nasdaq : PLRX

conferences

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s

RHEA-AI

neutral

05/09/22 4:05 PM

Nasdaq : PLRX

earnings

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

RHEA-AI

very positive

05/05/22 8:00 AM

Nasdaq : PLRX

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : PLRX

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective α v ß 6 /α v ß 1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential

RHEA-AI

very positive

05/02/22 8:00 AM

Nasdaq : PLRX

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Pliant selected for featured presentation at the ATS 2022 Respiratory Innovation Summit SOUTH SAN FRANCISCO, Calif.,

RHEA-AI

neutral

PLRX Data

Websitepliantrx.com
CeoBernard Coulie
Security namePliant Therapeutics Inc
Issue typecs
Sic code2834
Employees78
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Medicinal and Botanical Manufacturing
Address260 Littlefield Avenue
Address2Suite 150
StateCalifornia
CitySouth San Francisco
Zip94080
CountryUS
Phone16504816770

About Pliant Therapeutics Inc

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.